Medical network - June 1 in recent years, the traditional Chinese medicine act, the strategic plan for development of Chinese medicine (2016-2030) ", the "healthy China 2030" planning outline "and so on good policy of Chinese medicine continuously introduce, a promising industry. This kind of positive trend is reflected in the market of grade hospital, which will be used for reference for the top 100 varieties of pharmaceutical sales in the 2016 grade hospital. 

 

In 2016, the market for the pharmaceutical market for domestic grade hospitals was 141.7 billion yuan, up 7.5 percent year on year. Of these, the TOP100 has a sales of 83.6 billion yuan, accounting for 59.0 percent of the overall market for the pharmaceutical market, while TOP10 has a market share of 21.6 percent. For nearly four years, ginkgo biloba has been the top drug market in the ranking hospital, and the market share has been above 4%. 

 

Done in most varieties of category is the cardiovascular system, a total of 40, the 40 varieties of the size of the market totaled 44 billion yuan, and the whole level of domestic hospital cardiovascular system drugs proprietary Chinese medicine market size is 53 billion yuan, namely the 40 TOP100 varieties accounted for 83.0% of the whole category of scale. Followed by the anti-tumor and immune modulators, a total of 17 varieties for top100, total size is 14.7 billion yuan, accounting for the whole level of hospital in China 85.1% of the anti-tumor and immune modulators proprietary Chinese medicine market. 

 

Top 100 varieties of pharmaceutical sales in domestic grade hospitals in 2016.